Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.

During the autumn wave of the pandemic influenza virus A/(H1N1) 2009 (pIV) the German population was offered an AS03-adjuvanted vaccine. The authors compared results of two methods calculating the effectiveness of the vaccine (VE). The test-negative case-control method used data from virologic surve...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Helmut Uphoff, Matthias An der Heiden, Brunhilde Schweiger, Hartmut Campe, Dietmar Beier, Carina Helmeke, Martina Littmann, Walter Haas, Silke Buda, Daniel Faensen, Marcel Feig, Doris Altmann, Ole Wichmann, Tim Eckmanns, Udo Buchholz
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2011
Materias:
R
Q
Acceso en línea:https://doaj.org/article/54a93a63647a4de39dc301e3e0c78299
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:54a93a63647a4de39dc301e3e0c78299
record_format dspace
spelling oai:doaj.org-article:54a93a63647a4de39dc301e3e0c782992021-11-18T06:50:09ZEffectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.1932-620310.1371/journal.pone.0019932https://doaj.org/article/54a93a63647a4de39dc301e3e0c782992011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21789163/?tool=EBIhttps://doaj.org/toc/1932-6203During the autumn wave of the pandemic influenza virus A/(H1N1) 2009 (pIV) the German population was offered an AS03-adjuvanted vaccine. The authors compared results of two methods calculating the effectiveness of the vaccine (VE). The test-negative case-control method used data from virologic surveillance including influenza-positive and negative patients. An innovative case-series methodology explored data from all nationally reported laboratory-confirmed influenza cases. The proportion of reported cases occurring in vaccinees during an assumed unprotected phase after vaccination was compared with that occurring in vaccinees during their assumed protected phase. The test-negative case-control method included 1,749 pIV cases and 2,087 influenza test-negative individuals of whom 6 (0.3%) and 36 (1.7%), respectively, were vaccinated. The case series method included data from 73,280 cases. VE in the two methods was 79% (95% confidence interval (CI) = 35-93%; P = 0.007) and 87% (95% CI = 78-92%; P<0.001) for individuals less than 14 years of age and 70% (95% CI = -45%-94%, P = 0.13) and 74% (95% CI = 64-82%; P<0.001) for individuals above the age of 14. Both methods yielded similar VE in both age groups; and VE for the younger age group seemed to be higher.Helmut UphoffMatthias An der HeidenBrunhilde SchweigerHartmut CampeDietmar BeierCarina HelmekeMartina LittmannWalter HaasSilke BudaDaniel FaensenMarcel FeigDoris AltmannOle WichmannTim EckmannsUdo BuchholzPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 7, p e19932 (2011)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Helmut Uphoff
Matthias An der Heiden
Brunhilde Schweiger
Hartmut Campe
Dietmar Beier
Carina Helmeke
Martina Littmann
Walter Haas
Silke Buda
Daniel Faensen
Marcel Feig
Doris Altmann
Ole Wichmann
Tim Eckmanns
Udo Buchholz
Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.
description During the autumn wave of the pandemic influenza virus A/(H1N1) 2009 (pIV) the German population was offered an AS03-adjuvanted vaccine. The authors compared results of two methods calculating the effectiveness of the vaccine (VE). The test-negative case-control method used data from virologic surveillance including influenza-positive and negative patients. An innovative case-series methodology explored data from all nationally reported laboratory-confirmed influenza cases. The proportion of reported cases occurring in vaccinees during an assumed unprotected phase after vaccination was compared with that occurring in vaccinees during their assumed protected phase. The test-negative case-control method included 1,749 pIV cases and 2,087 influenza test-negative individuals of whom 6 (0.3%) and 36 (1.7%), respectively, were vaccinated. The case series method included data from 73,280 cases. VE in the two methods was 79% (95% confidence interval (CI) = 35-93%; P = 0.007) and 87% (95% CI = 78-92%; P<0.001) for individuals less than 14 years of age and 70% (95% CI = -45%-94%, P = 0.13) and 74% (95% CI = 64-82%; P<0.001) for individuals above the age of 14. Both methods yielded similar VE in both age groups; and VE for the younger age group seemed to be higher.
format article
author Helmut Uphoff
Matthias An der Heiden
Brunhilde Schweiger
Hartmut Campe
Dietmar Beier
Carina Helmeke
Martina Littmann
Walter Haas
Silke Buda
Daniel Faensen
Marcel Feig
Doris Altmann
Ole Wichmann
Tim Eckmanns
Udo Buchholz
author_facet Helmut Uphoff
Matthias An der Heiden
Brunhilde Schweiger
Hartmut Campe
Dietmar Beier
Carina Helmeke
Martina Littmann
Walter Haas
Silke Buda
Daniel Faensen
Marcel Feig
Doris Altmann
Ole Wichmann
Tim Eckmanns
Udo Buchholz
author_sort Helmut Uphoff
title Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.
title_short Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.
title_full Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.
title_fullStr Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.
title_full_unstemmed Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.
title_sort effectiveness of the as03-adjuvanted vaccine against pandemic influenza virus a/(h1n1) 2009--a comparison of two methods; germany, 2009/10.
publisher Public Library of Science (PLoS)
publishDate 2011
url https://doaj.org/article/54a93a63647a4de39dc301e3e0c78299
work_keys_str_mv AT helmutuphoff effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT matthiasanderheiden effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT brunhildeschweiger effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT hartmutcampe effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT dietmarbeier effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT carinahelmeke effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT martinalittmann effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT walterhaas effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT silkebuda effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT danielfaensen effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT marcelfeig effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT dorisaltmann effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT olewichmann effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT timeckmanns effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
AT udobuchholz effectivenessoftheas03adjuvantedvaccineagainstpandemicinfluenzavirusah1n12009acomparisonoftwomethodsgermany200910
_version_ 1718424291980083200